Microsoft word - eri 1109 sfi release.doc

FOR IMMEDIATE
PRESS RELEASE FROM FUTURE SCIENCE GROUP
Contact: Mary Yianni, Managing Commissioning Editor, Expert Reviews
Future Science Group
Tel: +44 (0) 20 8371 6090
Email: m.yianni@expert-reviews.com
Expert Review of Anti-infective Therapy features a
thought-provoking special focus issue on targeting
antibiotic resistance in Mycobacterium tuberculosis
Expert Review of Anti-infective Therapy has published a highly stimulating and original special focus issue on drugs targeting antibiotic resistance in Mycobacterium tuberculosis. The September issue of the journal presents a series of cutting-edge reviews on emerging trends in tuberculosis (TB) drug development. The global epidemic of TB continues to affect millions worldwide and the recent emergence of multidrug-resistant, extensively drug-resistant and even totally drug-resistant strains of M. tuberculosis has made the infection increasingly difficult to treat. New agents are urgently needed to treat this infection and traditional approaches to drug development involving screening novel compounds have yielded few promising drug candidates. The September special focus edition of Expert Review of Anti-infective Therapy, guest
edited by Liem Nguyen and Michael R. Jacobs (Case Western Reserve University School
of Medicine, Ohio, USA) attempts to tackle this critical issue. Bringing together articles
discussing novel approaches to new drug development whereby the molecular mechanisms
causing strains of M. tuberculosis to be resistant to antibiotics are investigated, the guest
editors aim to inform the development of novel therapeutics. As Liem Nguyen notes:
“Pharmaceutical inactivation of these resistance mechanisms might allow sensitization or
resensitization of M. tuberculosis to currently ineffective or inactive drugs. Recent attempts
to potentiate the antimycobacterial activities of B-lactams, ethionamide and folate
antagonists have raised hopes that this approach of targeting resistance might offer a
shortcut to broadening the chemotherapeutic options for TB treatment, thus decelerating
the dissemination of drug resistant TB forms.“
Of particular note in this special focus issue is a contribution from Charles Thompson and
Jan Burian (University of British Columbia, Vancouver, Canada) discussing the targeting of
WhiB7, a transcriptional activator that coordinates the physiology of intrinsic resistance to
several structural classes of antibiotics as a potential avenue for new anti-TB drugs. A
thought-provoking article from MM Viveiros et al. (University of Pennsylvania, PA, USA)
investigating the potential of inhibitors of mycobacterial efflux pumps as potential boosters
for TB drugs is also included.
“In an attempt to bring together many experts in this discussion, the editors hope that this special focus issue of Expert Review of Anti-Infective Therapy will shed light on the molecular mechanisms underlying these therapeutic strategies. The articles in this issue also discuss the feasibility and potential of this approach, and point out future directions in this area of TB research” comments Nguyen. The dedicated special focus issue will undoubtedly be of global interest to experts in infectious disease and drug development. Click here to access the special focus issue. Access to Expert Reviews of Anti-infective Therapy is available on a FREE 30-day trial
basis. To apply for your free trial please email info@expert-reviews.com quoting reference
ERI1009 to obtain password access.

-- ENDS --
For further information please contact:
Mary Yianni, Commissioning Editor, Future Science Group
T: +44 (0) 20 8371 6092 F: +44 (0) 20 8343 2313 E: m.yianni@expert-reviews.com

NOTES FOR EDITORS
ABOUT EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
Impact Factor: 3.283
Indexed on: MEDLINE & EMBASE
Expert Review of Anti-infective Therapy provides critical analysis and commentary on the
latest approaches to the management of bacterial, viral, fungal and parasitic infectious
diseases and the development of new anti-infective therapies.

Coverage includes:
• Effectiveness and safety of antibiotic agents • Understanding infectious diseases • New and emerging therapeutic approaches • Diagnostic technologies • Antimicrobial resistance • Hospital-borne infections • Increasing prevalence of viral infections • Concerns over the use of infectious agents as weapons of bioterrorism
ABOUT FUTURE SCIENCE GROUP
The Future Science Group (www.future-science-group.com) is an expanding group of
independent publishing companies active in the field of scientific information and endeavor,
including Expert Reviews Ltd (formerly known as Future Drugs Ltd) Future Medicine
Ltd and Future Science Ltd. As a leading provider of products and services for the medical,
science and business communities, we present the most important scientific breakthroughs
in an accessible and evaluated format, while at the same time providing the scientific
community with unique vehicles for disseminating forward thinking research information
and data. Complete listings of titles under each imprint are available at www.expert-
reviews.com, www.futuremedicine.com and www.future-science.com.

Source: http://www.expert-reviews.com/userimages/ContentEditor/1351610095661/ERI_Mycrobacterium.pdf